nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—HTR1D—meninx—peripheral nervous system neoplasm	0.0398	0.128	CbGeAlD
Lisuride—HTR1B—dura mater—peripheral nervous system neoplasm	0.0378	0.122	CbGeAlD
Lisuride—HTR1D—dura mater—peripheral nervous system neoplasm	0.0366	0.118	CbGeAlD
Lisuride—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.0214	0.0691	CbGeAlD
Lisuride—HTR1B—trigeminal nerve—peripheral nervous system neoplasm	0.0163	0.0525	CbGeAlD
Lisuride—HTR1D—trigeminal nerve—peripheral nervous system neoplasm	0.0157	0.0508	CbGeAlD
Lisuride—HTR1B—cranial nerve—peripheral nervous system neoplasm	0.0116	0.0374	CbGeAlD
Lisuride—HTR1D—cranial nerve—peripheral nervous system neoplasm	0.0112	0.0362	CbGeAlD
Lisuride—DRD5—ganglion—peripheral nervous system neoplasm	0.00947	0.0306	CbGeAlD
Lisuride—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.00782	0.0253	CbGeAlD
Lisuride—DRD1—nerve—peripheral nervous system neoplasm	0.00733	0.0237	CbGeAlD
Lisuride—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.00731	0.0236	CbGeAlD
Lisuride—DRD1—ganglion—peripheral nervous system neoplasm	0.00724	0.0234	CbGeAlD
Lisuride—HTR1B—ganglion—peripheral nervous system neoplasm	0.00586	0.0189	CbGeAlD
Lisuride—HTR1D—ganglion—peripheral nervous system neoplasm	0.00568	0.0183	CbGeAlD
Lisuride—HTR2C—ganglion—peripheral nervous system neoplasm	0.00562	0.0182	CbGeAlD
Lisuride—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.00557	0.018	CbGeAlD
Lisuride—HTR2A—pons—peripheral nervous system neoplasm	0.00551	0.0178	CbGeAlD
Lisuride—HTR1A—ganglion—peripheral nervous system neoplasm	0.00473	0.0153	CbGeAlD
Lisuride—DRD2—nerve—peripheral nervous system neoplasm	0.00433	0.014	CbGeAlD
Lisuride—DRD2—ganglion—peripheral nervous system neoplasm	0.00428	0.0138	CbGeAlD
Lisuride—DRD1—brainstem—peripheral nervous system neoplasm	0.00315	0.0102	CbGeAlD
Lisuride—HTR1B—trigeminal ganglion—peripheral nervous system neoplasm	0.00288	0.0093	CbGeAlD
Lisuride—HTR2A—nerve—peripheral nervous system neoplasm	0.00286	0.00922	CbGeAlD
Lisuride—HTR2A—ganglion—peripheral nervous system neoplasm	0.00282	0.00911	CbGeAlD
Lisuride—HTR1D—trigeminal ganglion—peripheral nervous system neoplasm	0.00279	0.009	CbGeAlD
Lisuride—HTR1B—brainstem—peripheral nervous system neoplasm	0.00255	0.00823	CbGeAlD
Lisuride—HTR1D—brainstem—peripheral nervous system neoplasm	0.00247	0.00797	CbGeAlD
Lisuride—HTR2C—brainstem—peripheral nervous system neoplasm	0.00244	0.00789	CbGeAlD
Lisuride—HTR1A—brainstem—peripheral nervous system neoplasm	0.00206	0.00664	CbGeAlD
Lisuride—ADRA2C—trigeminal ganglion—peripheral nervous system neoplasm	0.00204	0.00659	CbGeAlD
Lisuride—ADRA2C—parotid gland—peripheral nervous system neoplasm	0.00193	0.00622	CbGeAlD
Lisuride—DRD2—brainstem—peripheral nervous system neoplasm	0.00186	0.006	CbGeAlD
Lisuride—Ergonovine—ABCB1—peripheral nervous system neoplasm	0.00181	0.64	CrCbGaD
Lisuride—Malnutrition—Topotecan—peripheral nervous system neoplasm	0.00174	0.00318	CcSEcCtD
Lisuride—Mental disorder—Isotretinoin—peripheral nervous system neoplasm	0.00174	0.00318	CcSEcCtD
Lisuride—Mental disorder—Tretinoin—peripheral nervous system neoplasm	0.00174	0.00318	CcSEcCtD
Lisuride—Malnutrition—Tretinoin—peripheral nervous system neoplasm	0.00173	0.00316	CcSEcCtD
Lisuride—Malnutrition—Isotretinoin—peripheral nervous system neoplasm	0.00173	0.00316	CcSEcCtD
Lisuride—Dehydration—Cisplatin—peripheral nervous system neoplasm	0.00172	0.00315	CcSEcCtD
Lisuride—Pleural effusion—Epirubicin—peripheral nervous system neoplasm	0.00171	0.00313	CcSEcCtD
Lisuride—Weight increased—Alitretinoin—peripheral nervous system neoplasm	0.00171	0.00313	CcSEcCtD
Lisuride—Weight decreased—Alitretinoin—peripheral nervous system neoplasm	0.0017	0.00311	CcSEcCtD
Lisuride—Orthostatic hypotension—Cisplatin—peripheral nervous system neoplasm	0.00169	0.00309	CcSEcCtD
Lisuride—Weight decreased—Vincristine—peripheral nervous system neoplasm	0.00164	0.003	CcSEcCtD
Lisuride—ADRA2A—trigeminal ganglion—peripheral nervous system neoplasm	0.00163	0.00526	CbGeAlD
Lisuride—Sweating—Alitretinoin—peripheral nervous system neoplasm	0.00161	0.00294	CcSEcCtD
Lisuride—Pleural effusion—Doxorubicin—peripheral nervous system neoplasm	0.00158	0.0029	CcSEcCtD
Lisuride—Syncope—Tretinoin—peripheral nervous system neoplasm	0.00155	0.00283	CcSEcCtD
Lisuride—Syncope—Isotretinoin—peripheral nervous system neoplasm	0.00155	0.00283	CcSEcCtD
Lisuride—Sweating—Vincristine—peripheral nervous system neoplasm	0.00155	0.00283	CcSEcCtD
Lisuride—Abdominal discomfort—Cisplatin—peripheral nervous system neoplasm	0.00153	0.00281	CcSEcCtD
Lisuride—Palpitations—Tretinoin—peripheral nervous system neoplasm	0.00153	0.00279	CcSEcCtD
Lisuride—Palpitations—Isotretinoin—peripheral nervous system neoplasm	0.00153	0.00279	CcSEcCtD
Lisuride—Cough—Topotecan—peripheral nervous system neoplasm	0.00152	0.00278	CcSEcCtD
Lisuride—Cough—Tretinoin—peripheral nervous system neoplasm	0.00151	0.00276	CcSEcCtD
Lisuride—Cough—Isotretinoin—peripheral nervous system neoplasm	0.00151	0.00276	CcSEcCtD
Lisuride—Hallucination—Alitretinoin—peripheral nervous system neoplasm	0.0015	0.00274	CcSEcCtD
Lisuride—Cough—Melphalan—peripheral nervous system neoplasm	0.00149	0.00272	CcSEcCtD
Lisuride—Oedema peripheral—Alitretinoin—peripheral nervous system neoplasm	0.00148	0.00271	CcSEcCtD
Lisuride—Anxiety—Tretinoin—peripheral nervous system neoplasm	0.00147	0.00268	CcSEcCtD
Lisuride—Anxiety—Isotretinoin—peripheral nervous system neoplasm	0.00147	0.00268	CcSEcCtD
Lisuride—Hallucination—Vincristine—peripheral nervous system neoplasm	0.00144	0.00264	CcSEcCtD
Lisuride—Dry mouth—Isotretinoin—peripheral nervous system neoplasm	0.00144	0.00263	CcSEcCtD
Lisuride—Dry mouth—Tretinoin—peripheral nervous system neoplasm	0.00144	0.00263	CcSEcCtD
Lisuride—Confusional state—Isotretinoin—peripheral nervous system neoplasm	0.00142	0.0026	CcSEcCtD
Lisuride—Confusional state—Tretinoin—peripheral nervous system neoplasm	0.00142	0.0026	CcSEcCtD
Lisuride—Infection—Topotecan—peripheral nervous system neoplasm	0.00141	0.00258	CcSEcCtD
Lisuride—Infection—Isotretinoin—peripheral nervous system neoplasm	0.0014	0.00256	CcSEcCtD
Lisuride—Infection—Tretinoin—peripheral nervous system neoplasm	0.0014	0.00256	CcSEcCtD
Lisuride—Nervous system disorder—Topotecan—peripheral nervous system neoplasm	0.00139	0.00255	CcSEcCtD
Lisuride—Nervous system disorder—Tretinoin—peripheral nervous system neoplasm	0.00138	0.00253	CcSEcCtD
Lisuride—Nervous system disorder—Isotretinoin—peripheral nervous system neoplasm	0.00138	0.00253	CcSEcCtD
Lisuride—Infection—Melphalan—peripheral nervous system neoplasm	0.00138	0.00253	CcSEcCtD
Lisuride—Tachycardia—Tretinoin—peripheral nervous system neoplasm	0.00138	0.00252	CcSEcCtD
Lisuride—Tachycardia—Isotretinoin—peripheral nervous system neoplasm	0.00138	0.00252	CcSEcCtD
Lisuride—Hyperhidrosis—Topotecan—peripheral nervous system neoplasm	0.00137	0.00251	CcSEcCtD
Lisuride—Angiopathy—Alitretinoin—peripheral nervous system neoplasm	0.00136	0.0025	CcSEcCtD
Lisuride—Hyperhidrosis—Isotretinoin—peripheral nervous system neoplasm	0.00136	0.00249	CcSEcCtD
Lisuride—Hyperhidrosis—Tretinoin—peripheral nervous system neoplasm	0.00136	0.00249	CcSEcCtD
Lisuride—Tachycardia—Melphalan—peripheral nervous system neoplasm	0.00136	0.00248	CcSEcCtD
Lisuride—Anorexia—Topotecan—peripheral nervous system neoplasm	0.00135	0.00248	CcSEcCtD
Lisuride—Cardiac disorder—Vincristine—peripheral nervous system neoplasm	0.00134	0.00246	CcSEcCtD
Lisuride—Anorexia—Tretinoin—peripheral nervous system neoplasm	0.00134	0.00246	CcSEcCtD
Lisuride—Anorexia—Isotretinoin—peripheral nervous system neoplasm	0.00134	0.00246	CcSEcCtD
Lisuride—Anorexia—Melphalan—peripheral nervous system neoplasm	0.00133	0.00243	CcSEcCtD
Lisuride—Mental disorder—Alitretinoin—peripheral nervous system neoplasm	0.00132	0.00241	CcSEcCtD
Lisuride—Angiopathy—Vincristine—peripheral nervous system neoplasm	0.00131	0.0024	CcSEcCtD
Lisuride—Malnutrition—Alitretinoin—peripheral nervous system neoplasm	0.00131	0.00239	CcSEcCtD
Lisuride—Mediastinal disorder—Vincristine—peripheral nervous system neoplasm	0.00131	0.00239	CcSEcCtD
Lisuride—Insomnia—Tretinoin—peripheral nervous system neoplasm	0.00127	0.00233	CcSEcCtD
Lisuride—Insomnia—Isotretinoin—peripheral nervous system neoplasm	0.00127	0.00233	CcSEcCtD
Lisuride—Mental disorder—Vincristine—peripheral nervous system neoplasm	0.00127	0.00232	CcSEcCtD
Lisuride—Dyspnoea—Topotecan—peripheral nervous system neoplasm	0.00127	0.00232	CcSEcCtD
Lisuride—Dyspnoea—Tretinoin—peripheral nervous system neoplasm	0.00126	0.0023	CcSEcCtD
Lisuride—Dyspnoea—Isotretinoin—peripheral nervous system neoplasm	0.00126	0.0023	CcSEcCtD
Lisuride—Somnolence—Tretinoin—peripheral nervous system neoplasm	0.00125	0.00229	CcSEcCtD
Lisuride—Somnolence—Isotretinoin—peripheral nervous system neoplasm	0.00125	0.00229	CcSEcCtD
Lisuride—Dyspnoea—Melphalan—peripheral nervous system neoplasm	0.00124	0.00227	CcSEcCtD
Lisuride—Decreased appetite—Topotecan—peripheral nervous system neoplasm	0.00124	0.00226	CcSEcCtD
Lisuride—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.00123	0.00224	CcSEcCtD
Lisuride—HTR2A—brainstem—peripheral nervous system neoplasm	0.00123	0.00396	CbGeAlD
Lisuride—Decreased appetite—Isotretinoin—peripheral nervous system neoplasm	0.00123	0.00224	CcSEcCtD
Lisuride—Decreased appetite—Tretinoin—peripheral nervous system neoplasm	0.00123	0.00224	CcSEcCtD
Lisuride—Fatigue—Topotecan—peripheral nervous system neoplasm	0.00122	0.00224	CcSEcCtD
Lisuride—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.00122	0.00223	CcSEcCtD
Lisuride—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.00122	0.00223	CcSEcCtD
Lisuride—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.00122	0.00222	CcSEcCtD
Lisuride—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.00122	0.00222	CcSEcCtD
Lisuride—Constipation—Topotecan—peripheral nervous system neoplasm	0.00122	0.00222	CcSEcCtD
Lisuride—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.00121	0.00221	CcSEcCtD
Lisuride—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.00121	0.0022	CcSEcCtD
Lisuride—Constipation—Tretinoin—peripheral nervous system neoplasm	0.00121	0.0022	CcSEcCtD
Lisuride—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.0012	0.0022	CcSEcCtD
Lisuride—Fatigue—Melphalan—peripheral nervous system neoplasm	0.0012	0.00219	CcSEcCtD
Lisuride—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.00119	0.00217	CcSEcCtD
Lisuride—Syncope—Alitretinoin—peripheral nervous system neoplasm	0.00117	0.00215	CcSEcCtD
Lisuride—Feeling abnormal—Topotecan—peripheral nervous system neoplasm	0.00117	0.00214	CcSEcCtD
Lisuride—Feeling abnormal—Tretinoin—peripheral nervous system neoplasm	0.00116	0.00212	CcSEcCtD
Lisuride—Feeling abnormal—Isotretinoin—peripheral nervous system neoplasm	0.00116	0.00212	CcSEcCtD
Lisuride—Immune system disorder—Cisplatin—peripheral nervous system neoplasm	0.00116	0.00212	CcSEcCtD
Lisuride—Palpitations—Alitretinoin—peripheral nervous system neoplasm	0.00116	0.00212	CcSEcCtD
Lisuride—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.00115	0.00211	CcSEcCtD
Lisuride—Infection—Dactinomycin—peripheral nervous system neoplasm	0.00114	0.00209	CcSEcCtD
Lisuride—Cough—Alitretinoin—peripheral nervous system neoplasm	0.00114	0.00209	CcSEcCtD
Lisuride—Vertigo—Vincristine—peripheral nervous system neoplasm	0.00113	0.00207	CcSEcCtD
Lisuride—CYP2D6—brainstem—peripheral nervous system neoplasm	0.00112	0.00361	CbGeAlD
Lisuride—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.00112	0.00204	CcSEcCtD
Lisuride—Anxiety—Alitretinoin—peripheral nervous system neoplasm	0.00111	0.00203	CcSEcCtD
Lisuride—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.0011	0.00201	CcSEcCtD
Lisuride—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.00109	0.00199	CcSEcCtD
Lisuride—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.00109	0.00199	CcSEcCtD
Lisuride—Confusional state—Alitretinoin—peripheral nervous system neoplasm	0.00108	0.00197	CcSEcCtD
Lisuride—Angiopathy—Etoposide—peripheral nervous system neoplasm	0.00106	0.00195	CcSEcCtD
Lisuride—Infection—Alitretinoin—peripheral nervous system neoplasm	0.00106	0.00194	CcSEcCtD
Lisuride—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.00106	0.00194	CcSEcCtD
Lisuride—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.00106	0.00193	CcSEcCtD
Lisuride—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.00105	0.00192	CcSEcCtD
Lisuride—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.00104	0.00191	CcSEcCtD
Lisuride—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.00103	0.00189	CcSEcCtD
Lisuride—Infection—Vincristine—peripheral nervous system neoplasm	0.00102	0.00187	CcSEcCtD
Lisuride—Ergotamine—ABCB1—peripheral nervous system neoplasm	0.00102	0.36	CrCbGaD
Lisuride—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00102	0.00186	CcSEcCtD
Lisuride—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.00102	0.00186	CcSEcCtD
Lisuride—HTR1A—cerebellum—peripheral nervous system neoplasm	0.00101	0.00327	CbGeAlD
Lisuride—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.00101	0.00185	CcSEcCtD
Lisuride—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.00101	0.00185	CcSEcCtD
Lisuride—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.00101	0.00185	CcSEcCtD
Lisuride—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.001	0.00183	CcSEcCtD
Lisuride—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000998	0.00183	CcSEcCtD
Lisuride—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.000995	0.00182	CcSEcCtD
Lisuride—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000993	0.00182	CcSEcCtD
Lisuride—Anorexia—Vincristine—peripheral nervous system neoplasm	0.000981	0.00179	CcSEcCtD
Lisuride—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000966	0.00177	CcSEcCtD
Lisuride—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000952	0.00174	CcSEcCtD
Lisuride—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.00095	0.00174	CcSEcCtD
Lisuride—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000949	0.00174	CcSEcCtD
Lisuride—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000946	0.00173	CcSEcCtD
Lisuride—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00094	0.00172	CcSEcCtD
Lisuride—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000932	0.0017	CcSEcCtD
Lisuride—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000932	0.0017	CcSEcCtD
Lisuride—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000931	0.0017	CcSEcCtD
Lisuride—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000929	0.0017	CcSEcCtD
Lisuride—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000922	0.00169	CcSEcCtD
Lisuride—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000921	0.00168	CcSEcCtD
Lisuride—Vertigo—Etoposide—peripheral nervous system neoplasm	0.000918	0.00168	CcSEcCtD
Lisuride—DRD2—cerebellum—peripheral nervous system neoplasm	0.000916	0.00296	CbGeAlD
Lisuride—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000913	0.00167	CcSEcCtD
Lisuride—Infection—Cisplatin—peripheral nervous system neoplasm	0.000904	0.00165	CcSEcCtD
Lisuride—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000903	0.00165	CcSEcCtD
Lisuride—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000896	0.00164	CcSEcCtD
Lisuride—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000896	0.00164	CcSEcCtD
Lisuride—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000895	0.00164	CcSEcCtD
Lisuride—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000893	0.00163	CcSEcCtD
Lisuride—Cough—Etoposide—peripheral nervous system neoplasm	0.000892	0.00163	CcSEcCtD
Lisuride—ADRA2C—cerebellum—peripheral nervous system neoplasm	0.000891	0.00288	CbGeAlD
Lisuride—Headache—Topotecan—peripheral nervous system neoplasm	0.00089	0.00163	CcSEcCtD
Lisuride—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000889	0.00163	CcSEcCtD
Lisuride—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000888	0.00162	CcSEcCtD
Lisuride—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000887	0.00162	CcSEcCtD
Lisuride—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000885	0.00162	CcSEcCtD
Lisuride—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000884	0.00162	CcSEcCtD
Lisuride—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000883	0.00162	CcSEcCtD
Lisuride—Headache—Tretinoin—peripheral nervous system neoplasm	0.000883	0.00162	CcSEcCtD
Lisuride—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.00088	0.00161	CcSEcCtD
Lisuride—Constipation—Vincristine—peripheral nervous system neoplasm	0.00088	0.00161	CcSEcCtD
Lisuride—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.00088	0.00161	CcSEcCtD
Lisuride—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000869	0.00159	CcSEcCtD
Lisuride—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000868	0.00159	CcSEcCtD
Lisuride—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000841	0.00154	CcSEcCtD
Lisuride—Infection—Etoposide—peripheral nervous system neoplasm	0.000828	0.00152	CcSEcCtD
Lisuride—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000827	0.00151	CcSEcCtD
Lisuride—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000818	0.0015	CcSEcCtD
Lisuride—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000814	0.00149	CcSEcCtD
Lisuride—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000811	0.00148	CcSEcCtD
Lisuride—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000806	0.00147	CcSEcCtD
Lisuride—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000804	0.00147	CcSEcCtD
Lisuride—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000795	0.00145	CcSEcCtD
Lisuride—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000791	0.00145	CcSEcCtD
Lisuride—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000786	0.00144	CcSEcCtD
Lisuride—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000766	0.0014	CcSEcCtD
Lisuride—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.00075	0.00137	CcSEcCtD
Lisuride—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000748	0.00137	CcSEcCtD
Lisuride—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000744	0.00136	CcSEcCtD
Lisuride—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000743	0.00136	CcSEcCtD
Lisuride—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000741	0.00136	CcSEcCtD
Lisuride—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000739	0.00135	CcSEcCtD
Lisuride—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000732	0.00134	CcSEcCtD
Lisuride—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000725	0.00133	CcSEcCtD
Lisuride—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00072	0.00132	CcSEcCtD
Lisuride—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000719	0.00131	CcSEcCtD
Lisuride—Constipation—Etoposide—peripheral nervous system neoplasm	0.000713	0.0013	CcSEcCtD
Lisuride—ADRA2A—cerebellum—peripheral nervous system neoplasm	0.000711	0.0023	CbGeAlD
Lisuride—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000706	0.00129	CcSEcCtD
Lisuride—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000703	0.00129	CcSEcCtD
Lisuride—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000692	0.00127	CcSEcCtD
Lisuride—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000688	0.00126	CcSEcCtD
Lisuride—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000687	0.00126	CcSEcCtD
Lisuride—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000681	0.00125	CcSEcCtD
Lisuride—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000679	0.00124	CcSEcCtD
Lisuride—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000669	0.00122	CcSEcCtD
Lisuride—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000654	0.0012	CcSEcCtD
Lisuride—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000653	0.00119	CcSEcCtD
Lisuride—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.00065	0.00119	CcSEcCtD
Lisuride—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000648	0.00119	CcSEcCtD
Lisuride—Headache—Vincristine—peripheral nervous system neoplasm	0.000645	0.00118	CcSEcCtD
Lisuride—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000611	0.00112	CcSEcCtD
Lisuride—HTR2A—cerebellum—peripheral nervous system neoplasm	0.000604	0.00195	CbGeAlD
Lisuride—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.0006	0.0011	CcSEcCtD
Lisuride—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000598	0.00109	CcSEcCtD
Lisuride—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000597	0.00109	CcSEcCtD
Lisuride—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000594	0.00109	CcSEcCtD
Lisuride—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000593	0.00108	CcSEcCtD
Lisuride—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000579	0.00106	CcSEcCtD
Lisuride—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000576	0.00105	CcSEcCtD
Lisuride—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000573	0.00105	CcSEcCtD
Lisuride—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000565	0.00103	CcSEcCtD
Lisuride—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000552	0.00101	CcSEcCtD
Lisuride—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000551	0.00101	CcSEcCtD
Lisuride—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000551	0.00178	CbGeAlD
Lisuride—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00055	0.00101	CcSEcCtD
Lisuride—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000549	0.001	CcSEcCtD
Lisuride—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000533	0.000975	CcSEcCtD
Lisuride—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00053	0.00097	CcSEcCtD
Lisuride—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.00053	0.000969	CcSEcCtD
Lisuride—Headache—Etoposide—peripheral nervous system neoplasm	0.000522	0.000955	CcSEcCtD
Lisuride—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000515	0.000941	CcSEcCtD
Lisuride—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000514	0.000939	CcSEcCtD
Lisuride—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000506	0.000926	CcSEcCtD
Lisuride—Cough—Epirubicin—peripheral nervous system neoplasm	0.0005	0.000914	CcSEcCtD
Lisuride—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000486	0.000889	CcSEcCtD
Lisuride—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000477	0.000872	CcSEcCtD
Lisuride—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000476	0.000871	CcSEcCtD
Lisuride—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000475	0.000869	CcSEcCtD
Lisuride—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000471	0.000862	CcSEcCtD
Lisuride—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000468	0.000857	CcSEcCtD
Lisuride—Infection—Epirubicin—peripheral nervous system neoplasm	0.000464	0.000849	CcSEcCtD
Lisuride—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000462	0.000846	CcSEcCtD
Lisuride—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000458	0.000838	CcSEcCtD
Lisuride—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000456	0.000834	CcSEcCtD
Lisuride—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000452	0.000826	CcSEcCtD
Lisuride—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.00045	0.000822	CcSEcCtD
Lisuride—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000446	0.000815	CcSEcCtD
Lisuride—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000441	0.000807	CcSEcCtD
Lisuride—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000436	0.000798	CcSEcCtD
Lisuride—Infection—Doxorubicin—peripheral nervous system neoplasm	0.00043	0.000786	CcSEcCtD
Lisuride—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000424	0.000776	CcSEcCtD
Lisuride—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000423	0.000773	CcSEcCtD
Lisuride—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000422	0.000772	CcSEcCtD
Lisuride—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000418	0.000765	CcSEcCtD
Lisuride—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000417	0.000762	CcSEcCtD
Lisuride—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000416	0.00076	CcSEcCtD
Lisuride—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000412	0.000754	CcSEcCtD
Lisuride—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000406	0.000743	CcSEcCtD
Lisuride—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000404	0.000738	CcSEcCtD
Lisuride—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000403	0.000737	CcSEcCtD
Lisuride—Constipation—Epirubicin—peripheral nervous system neoplasm	0.0004	0.000731	CcSEcCtD
Lisuride—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000391	0.000715	CcSEcCtD
Lisuride—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000386	0.000705	CcSEcCtD
Lisuride—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000385	0.000705	CcSEcCtD
Lisuride—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000384	0.000703	CcSEcCtD
Lisuride—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000376	0.000688	CcSEcCtD
Lisuride—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000373	0.000683	CcSEcCtD
Lisuride—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000373	0.000682	CcSEcCtD
Lisuride—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.00037	0.000676	CcSEcCtD
Lisuride—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000356	0.000652	CcSEcCtD
Lisuride—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000335	0.000613	CcSEcCtD
Lisuride—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.00031	0.000568	CcSEcCtD
Lisuride—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000309	0.000565	CcSEcCtD
Lisuride—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000297	0.000544	CcSEcCtD
Lisuride—Headache—Epirubicin—peripheral nervous system neoplasm	0.000293	0.000536	CcSEcCtD
Lisuride—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000286	0.000523	CcSEcCtD
Lisuride—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.000503	CcSEcCtD
Lisuride—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000271	0.000496	CcSEcCtD
Lisuride—ADRA2B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.99e-05	0.000283	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.98e-05	0.000283	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	3.92e-05	0.000279	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.91e-05	0.000278	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.87e-05	0.000275	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.85e-05	0.000274	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.83e-05	0.000272	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.8e-05	0.00027	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	3.76e-05	0.000267	CbGpPWpGaD
Lisuride—ADRA2B—Hemostasis—TP53—peripheral nervous system neoplasm	3.76e-05	0.000267	CbGpPWpGaD
Lisuride—ADRA2A—Hemostasis—NRAS—peripheral nervous system neoplasm	3.73e-05	0.000265	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.73e-05	0.000265	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.7e-05	0.000263	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.68e-05	0.000262	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.67e-05	0.000261	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.65e-05	0.000259	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	3.64e-05	0.000258	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.63e-05	0.000258	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	3.62e-05	0.000257	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—GNAS—peripheral nervous system neoplasm	3.62e-05	0.000257	CbGpPWpGaD
Lisuride—ADRA2B—Hemostasis—HRAS—peripheral nervous system neoplasm	3.6e-05	0.000256	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.59e-05	0.000255	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.58e-05	0.000254	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.56e-05	0.000253	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—ABCB1—peripheral nervous system neoplasm	3.55e-05	0.000252	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.52e-05	0.00025	CbGpPWpGaD
Lisuride—ADRA2C—Hemostasis—TP53—peripheral nervous system neoplasm	3.51e-05	0.00025	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.51e-05	0.00025	CbGpPWpGaD
Lisuride—DRD5—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.49e-05	0.000248	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.46e-05	0.000246	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.46e-05	0.000246	CbGpPWpGaD
Lisuride—DRD5—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.39e-05	0.000241	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.38e-05	0.00024	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.36e-05	0.000239	CbGpPWpGaD
Lisuride—ADRA2C—Hemostasis—HRAS—peripheral nervous system neoplasm	3.36e-05	0.000239	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.36e-05	0.000239	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.33e-05	0.000236	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.3e-05	0.000234	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.3e-05	0.000234	CbGpPWpGaD
Lisuride—ADRA2B—Hemostasis—AKT1—peripheral nervous system neoplasm	3.18e-05	0.000226	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.17e-05	0.000225	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.12e-05	0.000222	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.12e-05	0.000222	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.11e-05	0.000221	CbGpPWpGaD
Lisuride—DRD5—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.08e-05	0.000219	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	3.07e-05	0.000218	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.07e-05	0.000218	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.07e-05	0.000218	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.03e-05	0.000215	CbGpPWpGaD
Lisuride—ADRA2C—Hemostasis—AKT1—peripheral nervous system neoplasm	2.97e-05	0.000211	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.93e-05	0.000208	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	2.89e-05	0.000205	CbGpPWpGaD
Lisuride—ADRA2A—Hemostasis—TP53—peripheral nervous system neoplasm	2.85e-05	0.000203	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.85e-05	0.000202	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.84e-05	0.000201	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.82e-05	0.0002	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.82e-05	0.0002	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.8e-05	0.000199	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.78e-05	0.000197	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.77e-05	0.000197	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.73e-05	0.000194	CbGpPWpGaD
Lisuride—ADRA2A—Hemostasis—HRAS—peripheral nervous system neoplasm	2.73e-05	0.000194	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.72e-05	0.000193	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.71e-05	0.000192	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.68e-05	0.00019	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.67e-05	0.00019	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.66e-05	0.000189	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.64e-05	0.000187	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.62e-05	0.000186	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.62e-05	0.000186	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.61e-05	0.000185	CbGpPWpGaD
Lisuride—HTR1D—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.6e-05	0.000185	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.59e-05	0.000184	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.59e-05	0.000184	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.57e-05	0.000183	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.57e-05	0.000183	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.55e-05	0.000181	CbGpPWpGaD
Lisuride—HTR1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.54e-05	0.000181	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.52e-05	0.000179	CbGpPWpGaD
Lisuride—DRD4—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.5e-05	0.000178	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.48e-05	0.000176	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.46e-05	0.000175	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.46e-05	0.000175	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.43e-05	0.000172	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.43e-05	0.000172	CbGpPWpGaD
Lisuride—ADRA2A—Hemostasis—AKT1—peripheral nervous system neoplasm	2.41e-05	0.000171	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.39e-05	0.00017	CbGpPWpGaD
Lisuride—HTR2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.39e-05	0.00017	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.38e-05	0.000169	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.37e-05	0.000168	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.36e-05	0.000168	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	2.36e-05	0.000168	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.35e-05	0.000167	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.35e-05	0.000167	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.32e-05	0.000165	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	2.31e-05	0.000164	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.31e-05	0.000164	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.31e-05	0.000164	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.29e-05	0.000162	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.29e-05	0.000162	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.27e-05	0.000161	CbGpPWpGaD
Lisuride—DRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.25e-05	0.00016	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.23e-05	0.000159	CbGpPWpGaD
Lisuride—DRD3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.22e-05	0.000158	CbGpPWpGaD
Lisuride—ADRA1D—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.22e-05	0.000158	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.21e-05	0.000157	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.2e-05	0.000156	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.2e-05	0.000156	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.19e-05	0.000156	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.17e-05	0.000154	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.16e-05	0.000153	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.15e-05	0.000153	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.14e-05	0.000152	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.11e-05	0.00015	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.11e-05	0.00015	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.1e-05	0.000149	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.1e-05	0.000149	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.08e-05	0.000148	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.08e-05	0.000148	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.06e-05	0.000147	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.06e-05	0.000146	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.05e-05	0.000145	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.05e-05	0.000145	CbGpPWpGaD
Lisuride—ADRB1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.03e-05	0.000144	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.02e-05	0.000143	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.02e-05	0.000143	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.01e-05	0.000143	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.01e-05	0.000143	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	2.01e-05	0.000143	CbGpPWpGaD
Lisuride—ADRA2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.01e-05	0.000143	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.01e-05	0.000143	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.99e-05	0.000142	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.99e-05	0.000141	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.98e-05	0.000141	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.98e-05	0.000141	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.97e-05	0.00014	CbGpPWpGaD
Lisuride—HTR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.94e-05	0.000138	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.94e-05	0.000138	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.93e-05	0.000137	CbGpPWpGaD
Lisuride—HTR2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.93e-05	0.000137	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.92e-05	0.000136	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.92e-05	0.000136	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.91e-05	0.000136	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.9e-05	0.000135	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.89e-05	0.000134	CbGpPWpGaD
Lisuride—ADRA2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.87e-05	0.000133	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.87e-05	0.000133	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.86e-05	0.000132	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.86e-05	0.000132	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.85e-05	0.000131	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.85e-05	0.000131	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.85e-05	0.000131	CbGpPWpGaD
Lisuride—ADRA1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.84e-05	0.000131	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.84e-05	0.000131	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.83e-05	0.00013	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.83e-05	0.00013	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.82e-05	0.000129	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.82e-05	0.000129	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.76e-05	0.000125	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.75e-05	0.000124	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.75e-05	0.000124	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.74e-05	0.000124	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.72e-05	0.000122	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.72e-05	0.000122	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.72e-05	0.000122	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.7e-05	0.000121	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.7e-05	0.000121	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.69e-05	0.00012	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.68e-05	0.000119	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.68e-05	0.000119	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000119	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.67e-05	0.000118	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.66e-05	0.000118	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.66e-05	0.000118	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.65e-05	0.000117	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.62e-05	0.000115	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.61e-05	0.000114	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.6e-05	0.000114	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.59e-05	0.000113	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.58e-05	0.000112	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.57e-05	0.000111	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.57e-05	0.000111	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.56e-05	0.000111	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.55e-05	0.00011	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.55e-05	0.00011	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.54e-05	0.00011	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.54e-05	0.00011	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.53e-05	0.000109	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.52e-05	0.000108	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.52e-05	0.000108	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.52e-05	0.000108	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.52e-05	0.000108	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.51e-05	0.000107	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.51e-05	0.000107	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.5e-05	0.000106	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.49e-05	0.000106	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.45e-05	0.000103	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.45e-05	0.000103	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.43e-05	0.000102	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.43e-05	0.000101	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.41e-05	0.0001	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.41e-05	0.0001	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.41e-05	0.0001	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.39e-05	9.9e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.39e-05	9.87e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.38e-05	9.82e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.37e-05	9.72e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.36e-05	9.69e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.35e-05	9.59e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.35e-05	9.59e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.34e-05	9.54e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.32e-05	9.35e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.29e-05	9.2e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.29e-05	9.14e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.28e-05	9.1e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.27e-05	9.06e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.26e-05	8.98e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.23e-05	8.74e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.23e-05	8.74e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.22e-05	8.7e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.22e-05	8.66e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.21e-05	8.59e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—peripheral nervous system neoplasm	1.2e-05	8.54e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.19e-05	8.47e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.19e-05	8.47e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.19e-05	8.46e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.18e-05	8.37e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.18e-05	8.36e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.17e-05	8.33e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.17e-05	8.32e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.14e-05	8.09e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.12e-05	7.96e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.09e-05	7.72e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.08e-05	7.68e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.08e-05	7.65e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.06e-05	7.55e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.04e-05	7.38e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.03e-05	7.35e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.03e-05	7.34e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.02e-05	7.22e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.01e-05	7.14e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.9e-06	7.03e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—peripheral nervous system neoplasm	9.77e-06	6.94e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.67e-06	6.87e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.25e-06	6.57e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.12e-06	6.48e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.98e-06	6.38e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.17e-06	5.8e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	6.37e-06	4.52e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	4.16e-06	2.96e-05	CbGpPWpGaD
